Karyopharm (KPTI) Q2 2026 Earnings Call Transcript

Karyopharm reported Q2 2026 total revenue of $33.4M (down from $37.9M YoY) as development reimbursement expired, while U.S. XPOVIO net product revenue rose to $30.8M from $29.7M. The company posted a $67.0M net loss (includes $44.5M non-cash mark-to-market items) and reiterated 2026 revenue guidance of $130M–$150M, but faces a $15.8M principal payment due Sept. 10, 2026, with a $10M minimum liquidity covenant—risk of default if not refinanced/waived. On the operational side, it pivoted away from endometrial cancer after the Phase 3 XPORT-EC-042 trial missed its primary endpoint and remains on track to submit an sNDA for selinexor+ruxolitinib in myelofibrosis in August 2026, supported by FDA feedback that SVR35 may serve as a reasonably likely surrogate for overall survival.

Analysis

KPTI is less a product story right now than a capital-structure trade. The equity is effectively a short-dated call option on two sequential de-riskers: lender forbearance and FDA procedural acceptance; without both, the stock can reprice toward restructuring value well before any commercial upside is realized. That makes the common unusually sensitive to dilution terms, not just clinical headlines.

The second-order winner from any credible approval path is not necessarily KPTI equity holders but KPTI’s lenders and, longer term, incumbent myelofibrosis players like INCY/Novartis if the combo broadens treatment intensity without forcing rapid share loss. The near-term loser is the existing shareholder base: even a “successful” financing likely comes at a punitive discount, so upside from regulatory optionality may be partially transferred to new capital providers.

The key reversal catalysts are narrow: a waiver/extension on the September debt payment, a clean sNDA filing with priority review acceptance, and a favorable NCCN/compendia signal over the next 1-3 months. The thesis breaks if the company misses financing terms, if FDA asks for material amendment, or if launch timing slips beyond early 2027, because the balance-sheet runway is too short for patience. Contrarian view: the market may be over-discounting the clinical package, but it is probably underpricing the probability that equity is diluted to save the option before it can monetize.

In short, this is not a normal biotech long; it is a financing-and-regulatory event chain where the most important variable is who funds the next 6-9 months.

Key Decisions for Investors

• Short KPTI common into any financing gap until a waiver/amendment is publicly confirmed; cover on a signed lender extension or equity raise that pushes the default date out by >6 months.
• If borrow is tight, use KPTI put spreads dated after the September debt deadline to express the default/dilution overhang with defined risk; thesis fails on a waiver plus non-dilutive financing.
• Watch for a post-filing squeeze only if the sNDA is accepted without major amendment and priority review is granted; in that case, consider a small tactical call spread rather than outright stock.
• Pair trade: long INCY versus short KPTI for a hedged myelofibrosis view — you get sector exposure without relying on KPTI’s refinancing execution; reassess if KPTI secures runway and launch visibility improves.